Ascletis Pharma Eulerpool naujienos

Ascletis Pharma Eulerpool News

Ascletis Pharma akcijų naujienos

Ascletis Pharma stebi daugybė žurnalistų ir investuotojų visame pasaulyje. Naujausias Ascletis Pharma naujienas mes pateikiame čia.

• rugsėjo 17 d. ·

  Yahoo
  Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity
• liepos 31 d. ·

  SeekingAlpha
  Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
• birželio 11 d. ·

  Yahoo
  Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
• balandžio 3 d. ·

  Yahoo
  Ascletis Announces Strategic Decisions on FXR agonist ASC42
• kovo 11 d. ·

  Yahoo
  Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
• sausio 28 d. ·

  SeekingAlpha
  Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China
• sausio 24 d. ·

  Yahoo
  Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
• sausio 23 d. ·

  Yahoo
  Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
• sausio 2 d. ·

  Yahoo
  Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
• gruodžio 5 d. ·

  Yahoo
  Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne